Dr. Brown on Blinatumomab Versus Chemotherapy as Post-Reinduction Therapy in B-ALL

Patrick Brown, MD



Patrick Brown, MD, chair of NCCN Guidelines for Adult and Pediatric ALL, and director of the Pediatric Leukemia Program at Sidney Kimmel Comprehensive Cancer Center, discusses the results of the randomized phase III Children’s Oncology Group Study AALL1331 trial of blinatumomab (Blincyto) versus chemotherapy as post-reinduction therapy in high- and intermediate-risk children and young adults with B-acute lymphoblastic leukemia in first relapse.

<<< View more from 2019 ASH Annual Meeting
Printer Printing...